Pankti Reid to Humans
This is a "connection" page, showing publications Pankti Reid has written about Humans.
Connection Strength
0.463
-
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases. Oncoimmunology. 2023; 12(1):2261264.
Score: 0.031
-
Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events. Oncologist. 2023 05 08; 28(5):440-448.
Score: 0.030
-
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events. JAMA Oncol. 2023 05 01; 9(5):723-724.
Score: 0.030
-
Role-Specific Curricular Needs for Identification and Management of Immune-Related Adverse Events. J Cancer Educ. 2023 10; 38(5):1486-1492.
Score: 0.030
-
Treatment of rheumatic adverse events of cancer immunotherapy. Best Pract Res Clin Rheumatol. 2022 12; 36(4):101805.
Score: 0.030
-
Immune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy. J Clin Rheumatol. 2022 Oct 01; 28(7):367-373.
Score: 0.029
-
Mortality Trends in Rheumatoid Arthritis: Zooming in on Interstitial Lung Disease. Ann Am Thorac Soc. 2021 12; 18(12):1953-1954.
Score: 0.027
-
Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study. J Immunother Cancer. 2021 09; 9(9).
Score: 0.027
-
Immune Checkpoint Inhibitor Therapy Toxicities-Reply. JAMA. 2021 07 06; 326(1):87-88.
Score: 0.027
-
Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report. J Med Case Rep. 2021 Mar 19; 15(1):124.
Score: 0.026
-
Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy. JAMA. 2021 Feb 02; 325(5):482-483.
Score: 0.026
-
Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis. Clin Exp Rheumatol. 2021 Nov-Dec; 39(6):1385-1393.
Score: 0.026
-
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia. Clin Pharmacol Ther. 2021 03; 109(3):688-696.
Score: 0.026
-
Teacher training for rheumatology fellows: a national needs assessment of fellows and program directors. Clin Rheumatol. 2020 Mar; 39(3):673-680.
Score: 0.024
-
JAK inhibitors and black box warnings: what is the future for JAK inhibitors? Expert Rev Clin Immunol. 2023 Jul-Dec; 19(11):1385-1397.
Score: 0.008
-
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors. Drug Saf. 2023 11; 46(11):1049-1071.
Score: 0.008
-
Anticitrullinated peptide antibody epitope expansion and the HLA DRB1 'shared epitope' are less common in seropositive checkpoint inhibitor-induced inflammatory arthritis than in longstanding rheumatoid arthritis. RMD Open. 2023 06; 9(2).
Score: 0.008
-
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis. 2023 07; 82(7):920-926.
Score: 0.008
-
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021 08 10; 326(6):499-518.
Score: 0.007
-
Socially optimal pandemic drug dosing. Lancet Glob Health. 2021 08; 9(8):e1049-e1050.
Score: 0.007
-
Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations. Gynecol Oncol. 2020 09; 158(3):531-537.
Score: 0.006
-
Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19. Clin Pharmacol Ther. 2020 09; 108(3):425-427.
Score: 0.006
-
Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors. Am J Kidney Dis. 2019 12; 74(6):853-856.
Score: 0.006
-
Facial Palsy Induced by Checkpoint Blockade: A Single Center Retrospective Study. J Immunother. 2019 04; 42(3):94-96.
Score: 0.006
-
Approach to Patients with Suspected Rheumatic Disease. Prim Care. 2018 Jun; 45(2):169-180.
Score: 0.005